Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

India — Central Drugs Standard Control Organisation

Tracked across 23 events · 341 articles · First seen Mar 20, 2025 · Last active Sep 23, 2026

Sentiment
14
Attention
6
Events
23
Relationships
4
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 0
Regulatory
The India — Central Drugs Standard Control Organisation issued a public advisory circular, dated September 21, warning against the indiscriminate, repeated or prolonged use of painkillers, particularly non-steroidal anti-inflammatory drugs (NSAIDs), and antibiotics, citing a…
Impact: The apex drug regulator is the primary issuer of the advisory, mandating prescription-only sales and supervised use of NSAIDs and antibiotics. Its action strengthens its regulatory stance but imposes compliance burdens on pharma and pharmacy retail.
Sep 22, 2026 · 20 articles
4 10
Regulatory
Impact: The regulator flagged the batch and ordered an investigation, demonstrating vigilance. Its actions may enhance its credibility but also highlight challenges in monitoring counterfeit drugs.
Sep 04, 2026 · 7 articles
6 0
Tech
Impact: The India — Central Drugs Standard Control Organisation>>> approved Zayn Malik>>> for import and marketing in India, providing Wockhardt>>> with a domestic market for its new antibiotic.
May 29, 2026 · 9 articles
4 0
Regulatory
Impact: The CDSCO is the Indian regulatory body that granted the approval, enabling the expanded use of Wegovy for MASH.
Jul 17, 2026 · 13 articles
3 0
Regulatory
Impact: CDSCO granted approval for the new indication, enabling Emcure to offer Poviztra for MASH treatment.
Jul 20, 2026 · 8 articles
4 0
Regulatory
Impact: CDSCO, under the Ministry of Health, conducted the scientific evaluation and granted marketing authorization for QDENGA, enabling its introduction in India.
Jul 20, 2026 · 93 articles
4 20
Regulatory
Impact: The India — Central Drugs Standard Control Organisation is collaborating with state regulators in India to curb malpractices in the GLP-1 drug supply chain.
Mar 24, 2026 · 11 articles
6 50
Regulatory
Impact: The India — Central Drugs Standard Control Organisation is responsible for strengthening manufacturing processes and avoiding compliance failures within India's pharmaceutical sector, contributing to the new regulations.
Jun 16, 2026 · 22 articles
4 50
Business
Impact: The India — Central Drugs Standard Control Organisation provided marketing authorization for Tanstrive, enabling its launch in India and ensuring regulatory compliance for the new drug.
Jun 25, 2026 · 7 articles
6 60
Domestic
Impact: The India — Central Drugs Standard Control Organisation collaborated in the development of the Drug Registry, ensuring standardization of medicine data across India's healthcare system.
Jun 27, 2026 · 32 articles
2 30
Regulatory
Impact: The national drug regulatory authority that will implement the digital platform, enhancing its efficiency and transparency.
Jul 31, 2026 · 7 articles
3 0
Regulatory
Impact: CDSCO conducted the inspection and issued the order to discontinue sales; it is enforcing drug regulations.
Jul 07, 2026 · 17 articles
1 -5
International
At a side event of the 81st session of the International — United Nations General Assembly titled Advancing Global Action to Eliminate Hepatitis, organized by the UN Group of Friends to Eliminate Hepatitis, Union Health…
Impact: It issued an advisory circular against indiscriminate use of NSAIDs and antibiotics over Chronic Kidney Disease risks, potentially curbing unregulated sales of these drugs in India.
Sep 23, 2026 · 6 articles
2 -10
Regulatory
Impact: The India — Central Drugs Standard Control Organisation alerted the India — Drugs Control Administration, Telangana, about the adulteration of Almont-Kid Syrup, playing a crucial role in identifying the issue.
Jan 10, 2026 · 6 articles
4 20
Business
Impact: CDSCO granted marketing authorisation for Leqembi, enabling its launch in India, reflecting its regulatory role.
Aug 03, 2026 · 6 articles
2 20
International
Impact: The India — Central Drugs Standard Control Organisation-Brazil — Brazilian Health Regulatory Agency MoU provides a regulatory framework for pharmaceutical market access, benefiting Indian drug exports.
Aug 31, 2026 · 7 articles
3 5
Business
Abbott Laboratories and Takeda Pharmaceutical Company announced on September 18, 2026 an exclusive distribution agreement under which Dr. Reddy's will promote and distribute Takeda's dengue vaccine QDENGA across India's private market for pediatric and adult…
Impact: India's drug regulator granted marketing authorisation for QDENGA in July 2026, enabling the subsequent distribution deal.
Sep 18, 2026 · 20 articles
4 50
Regulatory
Impact: The India — Central Drugs Standard Control Organisation is involved as the draft notification for the amendments is available on its website for stakeholder comments.
Jun 28, 2026 · 6 articles
2 20
Regulatory
Impact: The India — Central Drugs Standard Control Organisation is referenced as the regulatory body for novel medical devices, which are a priority area under the scheme. Its approval processes will be relevant for projects seeking to commercialize innovative devices.
Aug 28, 2026 · 6 articles
2 0
Regulatory
Impact: India — Central Drugs Standard Control Organisation is mentioned as a coordinating body for joint workshops and awareness campaigns under the MoU. Its involvement is supportive and not directly market-moving.
Aug 24, 2026 · 6 articles
2 5
Regulatory
The Bangladesh — Ministry of Health and Family Welfare issued an advisory dated September 16, 2026, to all States and Union Territories that have adopted the Clinical Establishments (Registration and Regulation) Act, 2010, regulating the…
Impact: As central licensing authority it has approved two CAR-T cell therapies, NexCAR19 and Qartemi, illustrating the approved-indication pathway.
Sep 17, 2026 · 20 articles
2 0
Business
Abbott Laboratories announced on September 17, 2026 a royalty-free, non-exclusive voluntary licensing agreement with Gilead Sciences covering investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP). The agreement is intended to support manufacturing readiness,…
Impact: Its subject expert committee recommended approval of lenacapavir in India, but final marketing approval for the drug is still pending.
Sep 17, 2026 · 6 articles
4 0
Tech
Impact: The India — Central Drugs Standard Control Organisation>>> has approved NaoTrac>>>, signifying its acceptance and quality for use in India.
May 26, 2026 · 6 articles
Bangladesh — Ministry of Health and Family Welfare ↔ India — Central Drugs Standard Control Organisation
Bangladesh — Ministry of Health and Family Welfare ↔ India — Central Drugs Standard Control Organisation
India ↔ India — Central Drugs Standard Control Organisation
India ↔ India — Central Drugs Standard Control Organisation
ERGEN INTELLIGENCE
Track India — Central Drugs Standard Control Organisation live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.